Please login to the form below

Not currently logged in
Email:
Password:

J&J to aquire Cougar

Johnson & Johnson has filed a tender offer statement with the Securities and Exchange Commission to purchase all outstanding shares

Johnson & Johnson has filed a tender offer statement with the Securities and Exchange Commission (SEC) to purchase all outstanding shares in Cougar Biotechnology. It reported its intent to acquire the Los Angeles-based biotech company in May this year.

Courgar's board of directors has unanimously approved the merger and, if the deal closes successfully, shareholders will receive $43 per share. The company in-licenses and develops clinical stage oncology drugs and currently has products in trials for prostate cancer, breast cancer, multiple myeloma and solid tumours.

The transaction is expected to close during the third quarter of 2009 and is subject to various conditions.

8th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics